血脂康对高脂血症患者血脂及血管内皮功能的影响

目的:观察血脂康对高脂血症患者血脂水平及血管内皮功能的影响.方法:98例高脂血症患者随机分为观察组49例和对照组49例.观察组口服血脂康胶囊,每天1.2g,连用8周;对照组口服普伐他汀片,每天20mg,连用8周.测定治疗前后两组血甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)及内皮素(ET)、一氧化氮(NO)水平.结果:治疗后,两组TG、TC、LDL-C、ET降低,HDL-C、NO升高,与治疗前比较,差异均有显著性意义(P<0.01或<0.05).观察组与对照组比较,治疗后TG、TC、LDL-C降低及HDL-C升高差异均无显著性意义,但ET降低和NO升高差异有显著性意义(P<0.05).结论:血脂康在改善高脂血症患者血脂异常同时可降低血内皮素、升高血一氧化氮水平,对血管内皮功能有改善作用.血脂康每天1.2g调脂程度与普伐他汀每天20mg相同,但改善血管内皮功能作用强于普伐他汀每天20mg.

Effect of Xuezhikang on Blood Liquids Level and Vascular Endothelial Function of Patients with Hyperlipidemia

Objective: To explore the effect of Xuezhikang on blood liquids level and vascular endothelial function of patients with hyperlipidemia. Methods: 90 cases with hyperlipidemia were divided randomly into observation group (45 cases) and contrast group (45 cases). The observation group took orally Xuezhikang capsules with 1.2g/d for 8 weeks, and the ontrast group took orally Pravachol tablets with 20mg/d for 8 weeks. Blood level of TG, TC, LDL-C, HLD-C, ET and NO were tested before and after treatment. Results: After treatment TG, TC, LDL-C and ET of both groups were decreased and HDL-C and NO increased. And the change had significant difference ( P <0.01 or ( P <0.05). Compared with that of treatment group, the decrease of TG, TC and LDL-C and increase of HDL-C had scarcely significant difference, while the decrease of ET and increase of NO had significant difference ( P <0.05).Conclusion: Xuezhikang can adjust the abnormal blood liquids and improve the end othelial function of patients with hyperlipidemia. The effect of Xuezhikang (1.2g/d) is similar to that of pravachol (20mg/d) in adjusting blood liquids, but stronger than the later in improving endothelial function.